Cytochrome P450 (P450) induction is often considered a liability in drug development. Using calibration curve-based approaches, we assessed the induction parameters R 3 (a term indicating the amount of P450 induction in the liver, expressed as a ratio between 0 and 1), relative induction score, C max /EC 50 , and area under the curve (AUC)/F 2 (the concentration causing 2-fold increase from baseline of the doseresponse curve), derived from concentration-response curves of CYP3A4 mRNA and enzyme activity data in vitro, as predictors of CYP3A4 induction potential in vivo. Plated cryopreserved human hepatocytes from three donors were treated with 20 test compounds, including several clinical inducers and noninducers of CYP3A4. After the 2-day treatment, CYP3A4 mRNA levels and testosterone 6b-hydroxylase activity were determined by real-time reverse transcription polymerase chain reaction and liquid chromatographytandem mass spectrometry analysis, respectively. Our results demonstrated a strong and predictive relationship between the extent of midazolam AUC change in humans and the various parameters calculated from both CYP3A4 mRNA and enzyme activity. The relationships exhibited with non-midazolam in vivo probes, in aggregate, were unsatisfactory. In general, the models yielded better fits when unbound rather than total plasma C max was used to calculate the induction parameters, as evidenced by higher R 2 and lower root mean square error (RMSE) and geometric mean fold error. With midazolam, the R 3 cut-off value of 0.9, as suggested by US Food and Drug Administration guidance, effectively categorized strong inducers but was less effective in classifying midrange or weak inducers. This study supports the use of calibration curves generated from in vitro mRNA induction response curves to predict CYP3A4 induction potential in human. With the caveat that most compounds evaluated here were not strong inhibitors of enzyme activity, testosterone 6b-hydroxylase activity was also demonstrated to be a strong predictor of CYP3A4 induction potential in this assay model.
Introduction
The potential for new drug candidates to exhibit drug-drug interactions (DDI) is a significant concern during the drug development process. Because metabolism by cytochrome P450 (P450) enzymes is often a major elimination pathway, small-molecule drug candidates are evaluated for P450 inhibition or induction at various stages of development. CYP3A4 is 15-30% of hepatic P450 content (Shimada et al., 1994; Ohtsuki et al., 2012) and is estimated to account for about half of oxidations in drugs undergoing P450-mediated clearance (Wienkers and Heath, 2005) . Therefore, this enzyme is critical to evaluate as a mediator of DDI.
Prediction of human DDI on the basis of in vitro data is another important goal during the early stages of drug development. Outcomes of these predictions may ultimately determine whether clinical DDI studies are conducted. Various models and frameworks have been proposed for induction prediction and these have been recently reviewed (Almond et al., 2009; Fahmi and Ripp 2010; Einolf et al., 2014) . These include calibration curve-based approaches, mathematical or mechanistic static models, and physiologically-based pharmacokinetic models. Calibration curve-based models can be developed by comparing the observed clinical change in area under the curve (AUC) of a probe substrate drug (such as midazolam for CYP3A4) for a set of known inducers/noninducers of the enzyme of interest, with various in vitro induction potency parameters, such as relative induction score (RIS) (Ripp et al., 2006) , AUC/F 2 (Kanebratt and Andersson 2008) , or C max /EC 50 (Fahmi and Ripp 2010) obtained from specific lots (donors) of cryopreserved hepatocytes. These models, as well as others (Kato et al., 2005; Shou et al., 2008 , Fahmi et al., 2009 , can be used to evaluate induction potential and risk of a clinical DDI. Recent guidance from the US Food and Drug Administration (FDA, 2012) and European Medicines Agency (EMA, 2013) suggest options for evaluating induction potential, ranging from simple, conservative models ("R 3 " and a predefined fold-induction threshold) to more complex models as mentioned earlier (e.g., mechanistic static models, physiologically-based pharmacokinetic models, RIS). Both guidance documents advocate use of mRNA data obtained using human hepatocytes. In addition, the documents generally recommend using donor lots that have been previously characterized with a sufficient number of clinical inducers and noninducers (EMA basic method being the exception).
Several in vitro test systems have been used for assessment and prediction of CYP3A4 induction potential in humans by new drug candidates. These systems include primary cultures of cryopreserved human hepatocytes (Shou et al., 2008; McGinnity et al., 2009; , human hepatocyte-like cell lines such as Fa2N-4 (Ripp et al., 2006; McGinnity et al., 2009) , HepaRG (Kanebratt and Andersson 2008; McGinnity et al., 2009) , and more recently a stably expressed human PXR cell line derived from HepG2 (Fahmi et al., 2012) . To date, human hepatocyte cultures have been considered the gold standard for in vitro induction assessment and are currently "preferred" by regulatory agencies.
The present work describes a direct comparison of several induction parameters (RIS, R 3 , C max /EC 50 , and AUC/F 2 ) generated with a set of clinical inducers and noninducers and using human hepatocytes as in vitro system, to predict the in vivo CYP3A4 induction potential from a calibration curve. In this approach, calibration curves were constructed by plotting various parameters versus the change in clinical probe AUC observed in vivo. The evaluations were conducted using endpoints of mRNA and testosterone 6b-hydroxylase activity generated using either total or unbound plasma C max in the models.
Materials and Methods
Materials and Reagents. A set of 20 compounds comprising primarily clinical inducers and noninducers were evaluated in vitro at concentrations selected on the basis of previous publications (Ripp et al., 2006; Kanebratt and Andersson 2008; McGinnity et al., 2009; (Table 1) and experience within this laboratory. Dimethyl sulfoxide (DMSO), testosterone, acetonitrile, ethanol, and all test drugs were purchased from Sigma-Aldrich (St. Louis, MO) and were of the highest grade available. Inducible cryopreserved human hepatocytes, Corning hepatocyte culture medium, 6b-hydroxytestosterone, 6b-hydroxytestosterone- [D 7 ], Corning high viability cryohepatocyte recovery kits, and collagen type I-coated 96-well plates were obtained from Corning Life Science (Tewksbury, MA). Gentamicin was obtained from Lonza (Walkersville, MD). Fungizone, L-glutamine, and Dulbecco's phosphate buffered saline were Gibco brand (Life Technologies, Grand Island, NY). The RNeasy 96 kit and DNase I were from Qiagen (Valencia, CA). Reverse transcription kit, two-step TaqMan PCR Master Reaction Mix, and primers/probes were obtained from Applied Biosystems (Foster City, CA).
Human Hepatocyte Culture and Treatment. Inducible cryopreserved human hepatocytes (lots 295, 312, and 318) were rapidly thawed and plated at a density of 0.6 Â 10 6 viable cells/ml (100 ml/well) in collagen type-I-coated 96-well plates using high viability cryohepatocyte recovery kits. After approximately 4 hours, the plating medium was replaced with 100 ml of hepatocyte culture medium supplemented with 2 mM L-glutamine, 50 mg/ml gentamicin, and 0.75 mg/ml fungizone, and the cultures were maintained overnight. Hepatocyte cultures were treated for 2 days with 0.1% DMSO (negative control) and test drugs at eight concentrations each with the exception of primaquine, methotrexate, and digoxin, for which three or four concentrations were tested. All incubations were performed in triplicate. The test concentration range is shown in Table 2 .
In Situ CYP3A4 Activity Measurement. The testosterone 6b-hydroxylase activity assay was performed essentially as described by Zhang et al. (2010) . Briefly, after treatment, hepatocyte cultures were washed with culture medium and incubated with 100 ml of culture medium containing CYP3A4 probe substrate testosterone at a concentration of 200 mM for 30 minutes. The reactions were stopped by combining an aliquot from each well with acetonitrile containing internal standard 6b-hydroxytestosterone- [D 7 ]. The amount of metabolite formed was determined by liquid chromatography-tandem mass spectrometry using an API-4000 mass spectrometer. The culture plates were stored at -80°C until total RNA isolation.
Determination of Test Drug Concentrations in Incubation Medium. At the end of the second day of treatment, the incubation medium from lot 295 was collected and combined with acetonitrile containing internal standard labetalol. The relative concentrations of test drug remaining in the incubation medium were quantitated by liquid chromatography-tandem mass spectrometry using an API-4000 mass spectrometer. Total RNA Isolation and Real-Time Reverse-Transcription Polymerase Chain Reaction Analysis. Total RNA was isolated from cells using the RNeasy 96 kit according to instructions provided by the manufacturer. The mRNA expression for CYP3A4 and the housekeeping gene b-actin was determined by Taqman real-time, reverse-transcription polymerase chain reaction (PCR) methods using the two-step assay protocol. First, a reverse transcription assay was performed using a GeneAmp PCR System 9700 (Applied Biosystems) with equal volumes of total RNA and the reverse-transcription master mixture. For the PCR assay, a PCR master mixture of reagents was prepared and a 20-ml aliquot of the master mixture was transferred to a 96-well optical reaction plate, followed by the addition of 5 ml of acquired cDNA to the appropriate wells. The PCR amplification was performed and the transcription was determined using an 7300 Real-Time PCR System.
Data Calculation. The test drug concentrations (micromoles) remaining in the incubation medium after the 2-day treatment and the catalytic activity for CYP3A4 in hepatocytes were calculated using standard curves. The fold induction for activity data were calculated as follows: (enzyme activity of test drug)/(mean of enzyme activity of negative control). The fold induction for mRNA data was determined using the calculation of 2 -DDCT (Livak and Schmittgen, 2001) . Percentages of positive control response for both activity and mRNA were calculated as follows: (mean of observed maximal fold -1)/(mean of observed maximal fold by rifampicin -1).
Curve Fitting. To estimate EC 50 , the maximum response (E max ), and F 2 values, concentration-response fold induction data were fitted to a sigmoid dose-response one-site-fit model (4 Parameter Logistic Model, Model 205) with XLfit (ID Business Solutions, Emeryville, CA) according to eq. 1:
where E min is the baseline of the curve, E max is the maximum effect, EC 50 is the concentration achieving 50% of E max , d is the slope of the curve, and C is the drug concentration. An additional parameter, F 2 , which is the drug concentration that causes a 2-fold increase of E min , was also calculated. The curve fitting was conducted using the following acceptance criteria and conditions: 1) Data points were excluded from curve fitting when toxicity, insolubility, and inhibition (enzyme activity only) were apparent or when the coefficient of variation of replicate values was .40% after removing the offending outlier in the original set of triplicate samples); 2) curve fitting data were not used when R 2 of the fit was ,0.85; 3) when no apparent plateau was observed after the above-mentioned conditions were taken into consideration, the E max was constrained to the observed maximal fold to prevent extrapolation of the curve fit beyond measured data, and EC 50 was then obtained from the fitted curves; 4) EC 50 and E max were determined only when fold induction was at least 1.4-fold and the response was concentration-dependent. The RIS and R 3 values were calculated according to eqs. 2 and 3, following to the European Medicines Agency (EMA, 2013) and Food and Drug Administration (FDA, 2012) guidance documents, respectively.
where [I] is total or unbound systemic plasma C max , and d is a scaling factor assumed to be 1 (FDA, 2012). Although R 3 as defined in FDA guidance does not permit use of unbound C max as the value of [I], as part of our investigation, we elected to examine the effect of both total and unbound C max on model outcomes.
The C max (total and unbound)/EC 50 and AUC/F 2 were also calculated, where AUC is the in vivo exposure of the interacting drug, represented by the area under the plasma concentration curve over the time course (Table 3) .
Preparation of Calibration Curves. A set of nine clinical inducers and clinical noninducers with known midazolam AUC changes after single dosing and clinical pharmacokinetic data were used for the preparation of calibration curves. The compounds included three strong inducers: rifampicin (with four clinical study data points), phenytoin, and carbamazepine; four moderate/weak inducers: troglitazone, terbinafine, pleconaril, and pioglitazone; and two clinical noninducers: nifedipine and clotrimazole (Table 3 , as indicated with asterisks). Flumazenil was excluded from the calibration curves because very weak induction was observed in only one of the three donors (mRNA only) and its extremely low C max would have yielded a data point far removed from the range of the other points on the calibration curve. The remaining interacting drugs examined here were not used to generate the calibration curves. This is because we used only those compounds for which associated clinical data were obtained with the well established CYP3A4 probe midazolam as the victim drug (see Prediction of CYP3A4 Induction Using Calibration Curves 1381 at ASPET Journals on April 12, 2017 dmd.aspetjournals.org Table 3 ). In vitro data generated for those compounds with non-midazolam clinical data were then evaluated against the curve generated with the aforementioned nine compounds. The calibration curves were constructed with the observed midazolam AUC change against calculated induction parameters (RIS, R 3 , C max / EC 50 , and AUC/F 2 ) using eq. 4:
where A is the baseline of the curve constrained to 0%, B is the maximum AUC change constrained to #100%, C is the values of induction parameters x (RIS, R 3 , C max /EC 50 , and AUC/F 2 ) achieving 50% of AUC, change and d is the slope of the curve. The cut-off values for a positive inducer were defined as the induction parameter values leading to a 20% decrease in predicted midazolam AUC change (FDA, 2012) . The analysis included determination of the 95% confidence interval for the cut-off values (95% probability that the predicted cut-off values will occur) and correlation coefficient (R 2 ) for goodness of fit. Statistical parameters were determined using the Statistics Designer function with in XLfit software.
Comparison of Model Predictability. To compare the prediction accuracy of each model, the root mean square error (RMSE) was calculated as described in eq. 5, with greater accuracy being shown by the lower RMSE. The fold changes of predicted DDI and the observed DDI were calculated as AUC induced /AUC control . The bias of the prediction models was determined by the geometric mean fold error (GMFE) in eq. (6), which weighs over-and underpredictions equally. The lowest GMFE value would represent the lowest prediction bias. 
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Results
Concentration-Dependent Induction Response of CYP3A4 mRNA and Activity in Human Hepatocytes. Hepatocytes from lots 295 (aged 41, female and Caucasian), 312 (aged 56, male and Caucasian), and 318 (aged 58, male and African American) were treated for 2 days with a medium change and compound replenishment after 24 hours. Both CYP3A4 mRNA levels and catalytic activities were measured. The parameters EC 50 , E max , and F 2 were determined from the concentration-response curves, and percentage of positive control response was also determined. Overall, EC 50 values obtained from both CYP3A4 mRNA and enzyme activity were similar (e.g., within 3-fold) within and between donors, with some notable exceptions (Tables 1 and  2) . For example, EC 50 for rifampicin was 0.12 and 0.18 for mRNA and enzyme activity, respectively, for lot 295, but was 1.4 and 1.1 mM for the same endpoints, respectively, for lot 312. E max values obtained from mRNA data in general were greater than those from the activity results. The weak clinical inducers sulfinpyrazone and probenecid produced a potent induction response of CYP3A4 mRNA and/or activity and the response did not reach plateau at the highest concentration within any of the lots (data not shown). Flumazenil caused no induction for both mRNA and activity in lots 295 and 318; however, a slight induction response for CYP3A4 mRNA was observed in lot 312 at the high end of the concentration-response curve. As expected, most compounds previously shown to be inducers in vivo and in vitro caused a greater than 2-fold induction over vehicle control and exhibited concentration-dependence, the criteria to demonstrate a positive induction result as described in the EMA guidance (EMA, 2013) . A few moderate and/or weak clinical inducers, such as pleconaril and pioglitazone, failed to reach cut-off values for either mRNA or enzymatic activity for some of the three lots of hepatocytes. Quinidine at the concentration range of 0.11-250 mM caused an induction of CYP3A4 mRNA in two of the three lots but not for enzyme activity for all lots. No induction of CYP3A4 mRNA and activity was observed for primaquine, methotrexate, and digoxin at the concentrations tested in any of the three lots. The RIS values were calculated on the basis of both total and unbound C max . The interacting drugs used for the curve fitting are shown in Table 3 . See Supplemental Data for lots 312 and 318. 
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Comparison of Calibration Curves for RIS, R 3 , C max /EC 50 , and AUC/F 2 . To examine the relationship between induction data generated in vitro and data observed in clinical studies (Table 3) , the RIS, R 3 , and C max /EC 50 values were calculated on basis of both total and unbound C max ( Supplemental Tables 1-3; Table 5 ). The calibration curves were then prepared with the percentage observed AUC changes of midazolam as a function of parameters RIS, R 3 , C max /EC 50 , and AUC/F 2 as shown in Figs. 1-4 (see Supplemental Figs. 1-8 for lots 312 and 318). The proposed cut-off values corresponding to a 20% of predicted midazolam AUC change in vivo, 95% confidence interval for the cut-off values, and correlation coefficient R 2 for the calibration curves are summarized in Table 4 . Overall, excellent correlation between the induction parameters and observed midazolam AUC changes was obtained with the choice of model with reasonable 95% confidence intervals and R 2 values (0.84-0.995 for mRNA and 0.78-0.99 for activity). Cut-off values were within 3-fold for both mRNA and activity across all three lots for RIS, R 3 , and C max /EC 50 . Relative to other parameters, the cut-off values for AUC/F 2 appeared to vary more across all three lots of hepatocytes.
Assessment of R 3 Cut-Off Value in Prediction of CYP3A4 Inducers. The R 3 values for each interacting drug were calculated on the basis of both total and unbound C max and are presented in Table 5 . These values were compared with 0.9, a cut-off value for a likely inducer in vivo as proposed in the FDA draft guidance (FDA, 2012). As shown in Table 5 , R 3 values calculated with both total systemic plasma concentration (C max-t ) and unbound systemic plasma concentration (C max-u ) classified the strong clinical inducers well but were less accurate in categorizing midrange or weak inducers. For example, using C max-t , the calculated R 3 values for some of clinical noninducers such as nifedipine, rosiglitazone, omeprazole, and quinidine were ,0.9, resulting in false positive assignments. In contrast, R 3 values calculated on the basis of C max-u were .0.9 for some moderate and weak inducers, such as troglitazone, terbinafine, pleconaril and pioglitazone, leading to false negative assignments. This was true of all three donors regardless of using mRNA or activity as the endpoint.
Predicted AUC Changes Using the Calibration Curves. Using the constructed calibration curves, the AUC changes for 16 interacting drugs were predicted from all three lots and compared with the observed AUC changes (Figs. 5-7; Supplemental Tables 4-7) . As expected, the predicted AUC changes were close to fitted values for the nine drugs interacting with midazolam as the victim drug, although a slight overprediction was observed for troglitazone and terbinafine using RIS and R 3 , calculated on the basis of C max-t (both activity and mRNA) in some of these lots. The correlation plots between the observed and predicted midazolam AUC changes for three hepatocyte lots were prepared for all induction parameters (Figs. 5-7) . As anticipated, a strong correlation (R 2 = 0.85-0.97) for both mRNA and activity was obtained with the observed AUC changes, regardless of the parameters used. No obvious difference in the robustness of the prediction in midazolam AUC changes was observed using the mRNA versus the activity data. The prediction accuracy and bias for each model were analyzed by RMSE and GMFE using a set of data from both three lots and a single lot. Table 6 shows similar GMFE and RMSE values calculated from this set of three lots for the different prediction methods using mRNA or activity as the measured endpoint. RMSE and GMFE analysis from a single lot provided similar results (data not shown). We found that the correlation was largely improved for all parameters (RIS, R 3 , and C max /EC 50 ) for both mRNA and activity (R 2 . 0.94) when using C max-u . Consistent with these observations, lower RMSE and GMFE values were obtained when using C max-u instead of C max-t in the prediction methods (Table 6 ). No apparent correlation was observed between the observed midazolam or nonmidazolam AUC changes and percentage of positive control response for both activity and mRNA for all three lots (R 2 = 0.13-0.41) (Fig. 8) .
The prediction for the interacting drugs with nonmidazolam victim drugs was also conducted with these calibration curves. Weak correlations between the observed and predicted nonmidazolam AUC changes for three hepatocyte lots for all induction parameters were found (Figs. 5-7) (R 2 , 0.40). However, parameters predicted clinical noninducers reasonably well except for quinidine, where a significant overprediction (32-93% midazolam AUC change) was found using RIS, R 3 , and C max /EC 50 , generated from mRNA data on the basis of C max-u for lots 295 and 312. However, no Summary of cut-off values, confidence interval, and correlation coefficients (R2) of calibration curves for RIS, R3, Cmax/EC50, and AUC/F2 RIS, R 3 , C max /EC 50 were calculated using both C max-t and C max-u . Cut-off values for RIS, R 3 , C max /EC 50 and AUC/F 2 were defined as that corresponding to 20% predicted AUC change.
Hepatocyte
Lot No. Parameters induction was predicted with AUC/F 2 from both mRNA and activity data for quinidine across all three lots. For moderate/weak inducers, the AUC change for nonmidazolam drugs was predicted with varied accuracy. In general, the prediction accuracy was lower and bias was greater in the prediction of the AUC change of CYP3A substrates that were not midazolam. This is evident in the lower RMSE and GMFE values for midazolam trials, as shown in Table 6 . In a few cases, either over-or underprediction was also observed for the in vivo AUC changes of nifedipine by phenobarbital, alprazolam by carbamazepine, and simvastatin by troglitazone and pioglitazone, depending on parameters and hepatocyte lots ( Supplemental Tables 4-7 ). Significant overprediction was consistently found for the AUC changes of R-warfarin by sulfinpyrazone (22% observed AUC change versus 59-94% predicted midazolam AUC change) and of carbamazepine by probenecid (20% observed AUC change versus 70-94% predicted midazolam AUC change), with all parameters for both activity and mRNA across all lots except for AUC/F 2 for lot 318 ( Supplemental Tables 4-7) .
Concentration of Test Compounds in the Medium. The results of such testing in the present study are shown in Supplemental Table 8 for lot 295. Within this set of compounds, concentrations ranged from close to nominal to well below nominal.
Discussion
In this study, model compounds were evaluated for CYP3A4 induction in human hepatocytes and calibration curves constructed to predict responses in vivo. As expected, we observed notable interdonor differences in EC 50 and E max values (e.g., rifampicin EC 50 values), which supports regulatory agency guidance recommending calibration of hepatocyte donors for response with a set of inducers and noninducers. Using resulting calibration curves, inducers were predicted with variable accuracy, whereas noninducers were generally well predicted.
Isolated false positive and false negative outcomes were observed. For example, phenobarbital was predicted as a noninducer with the victim drug nifedipine when the calibration curves of total C max /EC 50 from the enzyme activity and/or mRNA data were used (lots 295 and 312). As phenobarbital is a clinical inducer, these results suggest that evaluating multiple parameter endpoints would be conservative. Quinidine was also incorrectly classified as an in vivo inducer when mRNA was used as the predictor in the RIS, R 3 , and C max /EC 50 calibrationcurve models obtained on the basis of C max-u with donors 295 and 312. This outcome was attributable to the concentration-dependent induction response of CYP3A4 mRNA, but not activity. Quinidine has been classified as a moderate CYP3A4 inhibitor in vivo (Isoherranen et al., 2012) , suggesting that any induction in vivo could be masked. These data highlight the value of acquiring enzyme activity results to help one consider additional, more complex models. For example, the "net-effect" model (Fahmi et al., 2009 ) incorporates parameters of competitive and time-dependent inhibition that may provide a more informed prediction of clinical DDI.
Our data also suggest that midazolam calibration curves may overpredict AUC changes of nonmidazolam victim drugs for weak/ moderate inducers, as evidenced by higher midazolam AUC change compared with those obtained with other victim drugs. This is illustrated Fig. 7 . Correlation analysis of observed midazolam and nonmidazolam AUC change (%) and predicted AUC changed (%) from AUC/F 2 derived from CYP3A4 mRNA (A) and enzyme activity (B) for three lots of human hepatocytes. Solid black line represents unity. Dashed lines represent the boundary denoting predicted changes within 620% of observed. The data points outside of these lines were considered either underor overpredicted.
TABLE 6
Accuracy and bias in the prediction of clinical CYP3A induction of midazolam and nonmidazolam CYP3A substrates using the calibration-curve based approaches
The predicted fold changes in AUC from all three hepatocyte lots were used in the calculations. with predictions of alprazolam AUC change by carbamazepine and simvastatin AUC change by pioglitazone and troglitazone (Table 3 ; Supplemental Tables 4-7) . Similarly, significant overprediction of in vivo response using the midazolam curve was found for sulfinpyrazone and probenecid compared with the observed responses with victim drugs, R-warfarin and carbamazepine. This finding was consistent for all three hepatocytes lots with all modeled induction parameters with exception of AUC/F 2 for lot 318, regardless of activity or mRNA endpoint. Fahmi et al. (2012) also reported an overprediction for sulfinpyrazone using midazolam-RIS calibration curves in DPX2 cells. As midazolam exhibits a very high fraction of metabolized CYP3A (f m , CYP3A ), it is likely more susceptible to CYP3A4 induction than victim drugs (e.g., R-warfarin) cleared by additional pathways (Ripp et al., 2006; Xu et al., 2011) . These findings underscore the use of midazolam as a preferential and sensitive clinical probe for DDI investigations. Notably, two clinically weak inducers, pioglitazone and pleconaril failed to always reach the 2-fold minimum induction response in vitro that would classify a compound as an inducer according to EMA guidance. However, this criterion was met for one or more of the other donors underscoring the value of using three donors in the standard test. All calculated induction parameters incorporated in vivo total or unbound plasma concentrations of the interacting drugs. Regulatory guidance from the EMA (2013) and FDA (2012) recommend that C max-u be used for RIS calculation and C max-t for the R 3 calculation, respectively. Our results showed that the AUC changes were reasonably well predicted when using either C max-t or C max-u to calculate parameters and was the case for both mRNA and enzyme activity. However, use of C max-u resulted in a better correlation between observed and predicted midazolam AUC change (Figs 5, 6, 7) with an improved accuracy and precision of predicting the DDI, as RMSE and GMSE were lower (Table 6 ). These observations are consistent with a previous report (Ripp et al., 2006) . Conversely, Fahmi et al. (2012) demonstrated that use of total systemic drug concentration in an RIS evaluation resulted in significant improvement in DDI correlations in DPX2 cells, possibly attributable to inclusion of 10% serum in the incubation medium that likely affected the free fraction in the medium.
Methods
Midazolam
The FDA draft guidance (FDA, 2012) indicates that an investigational drug is likely to be a P450 inducer when the calculated R 3 value is below 0.9. We showed that R 3 cut-off values predicting a 20% midazolam AUC change (e.g., a DDI) were much lower than 0.9 (ranging from 0.44 to 0.65 for CYP3A4 mRNA, as well as enzyme activity, across the three lots). Accordingly, we observed a relatively high rate of false positives (e.g., up to 50% exhibited R 3 , 0.9). When R 3 values were calculated using C max-u , we found several false negative outcomes (Table 5 ). These data indicate that the 0.9 cut-off value along with the prescribed use of C max-t proposed by the FDA is conservative. In our evaluation we set the scaling factor d equal to 1, as this is the "assumed" value according to the guidance. Modifying the d value (or the R 3 cut-off value) may improve the accuracy of the classifications.
Both regulatory agency guidance documents recommend mRNA as the endpoint for testing induction potential. showed that the measurement of CYP3A4 mRNA was more sensitive in detecting induction in hepatocytes compared with enzyme activity, while both endpoints were found effective at classifying clinical induction response. Our results support a similar conclusion. In general, we selected compounds in our test set biased away from potent inhibitors of CYP3A4 enzyme, to avoid the potentially confounding effects of enzyme inhibition. Clotrimazole, which was shown to exhibit a K i value for liver microsomal CYP3A4 of 0.25 nM (Gibbs et al., 1999) , is the notable exception. In this case, metabolic depletion and/or the wash steps conducted prior to testosterone addition likely precluded significant inhibition. Enzyme activity alone would probably have limited value as a predictor when compounds found to strongly or irreversibly inhibit enzyme activity within hepatocytes (e.g., ritonavir) are examined, as this may not always show a corresponding result in vivo (Kirby et al., 2011) . Both midazolam (in vivo probe) and testosterone (in vitro probe) are substrates of CYP3A5 (Williams et al., 2002) . This weakly inducible enzyme ) exhibits polymorphic expression [e.g., expressed in 10-30% of Caucasians and 50-70% of African Americans (Daly, 2006) ]. Whether clinical subject and hepatocyte-donor CYP3A5genotype status would help explain some variability in the models is not known.
Calculations of F 2 , RIS, R 3 , and C max /EC 50 , require preparation of a dose-response curve, ideally with sigmoidal shape and well defined maxima and minima. While minima were reasonably well defined, we noted that approximately 70% of compounds did not reach clear maxima, likely owing to compound incomplete solubility, cytotoxicity, enzyme inhibition, or a combination thereof. In about 15% of the curves, a plateau was not reached because the concentration range was likely insufficient. For these cases, we deployed a strategy of constraining E max to the observed maximal fold induction level that exhibited no evidence of insolubility or cytotoxicity; the EC 50 parameter was then obtained from the curve-fitting model. An alternative approach to not reaching well defined maxima is to use the slope of the curve or AUC/F 2 as predictors (Kanebratt and Andersson, 2008; Shou et al., 2008) . Our data support the value of obtaining the AUC/F 2 parameter.
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In an in vitro induction assay, nominal and final (e.g., at the end of the treatment period) intracellular concentrations may differ and could impact model predictivity. Differences may be attributable to cellular uptake, metabolic depletion, compound degradation, binding to cellular components or the plate, or a combination of these. As recommended by the EMA guidance, we investigated drug concentrations in the medium on the last day of incubation. For 11 out of 17 compounds, concentrations were within approximately 2-fold of nominal at the concentrations closest to the reported C max-u . However, six compounds exhibited concentrations ,20% of nominal (Supplemental Table 8 ), suggesting that intracellular unbound concentrations were substantially less than those used to derive EC 50 and E max . When we used the time-weighted average concentrations to derive these parameters, in general, EC 50 values were lower and E max values were unchanged. Somewhat surprisingly, this exercise showed no improvement on RMSE and GMFE for any parameter (data not shown).
In conclusion, in vivo CYP3A4 induction responses were well predicted by the plated-hepatocyte model, using parameters RIS, R 3 , C max /EC 50 , and AUC/F 2 in calibration curve-based models. Our data provide no strong basis for selecting a preferential model for predicting an induction response, although AUC/F 2 was somewhat less accurate and exhibited higher prediction bias. Enzyme activity and mRNA were equally effective as endpoints. If only one endpoint can be generated, mRNA is preferred, because of the potential confounding effects of enzyme inhibition. However, we found examples (e.g., quinidine) where integrating results of both mRNA and enzyme activity could provide a higher level of confidence in the evaluation compared with either endpoint alone. In a general evaluation scheme, considering the resources needed to construct calibration curves as well as the potential need for range-finding, we would suggest using a three-donor screening test to first classify a potential inducer from a basic method (such as described in the EMA guidance), followed by the more comprehensive RIS testing in calibrated hepatocytes for those compounds exhibiting induction.
